Eyeing a big heart failure market, scPharmaceuticals aims for $100M IPO

After lining up an application for FDA approval of a new approach to treating fluid retention in heart failure patients a few months ago, Burlington, MA-based scPharmaceuticals is shooting for a $100 million IPO.

The biotech has developed a new formulation of furosemide so it could be delivered via a wearable device, rather than delivered through an IV in the hospital. The combo has the simple intention of reducing the number of days a patient has to be hospitalized for therapy — in a heart failure market that accounts for millions of patients — and the biotech has plans for more IV-replacement programs much like it.

The first NDA was field in August, according to the S-1.

Next in line are two antibiotics: scCeftriaxone, an antibiotic currently used intravenously for the treatment of infections caused by gram-positive and gram-negative organisms. And there’s another program for scCarbapenem.

The venture backed biotech had burned through close to $55 million through the end of last June.

Here are the venture groups with the biggest stakes in this biotech’s future: 5AM Ventures, which owns 23.2% of the company, Lundbeckfond, 22.6%, OrbiMed, 23% and Sun Pharmaceutical, 16%.

Biotech IPOs are going and blowing in Q4, offering a shot at some major financing events for drug and device makers.

The best place to read Endpoints News? In your inbox.

Full-text daily reports for those who discover, develop, and market drugs. Join 21,000+ biopharma pros who read Endpoints News by email every day.

Free Subscription